How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cancer Antibody Drug Conjugates Market
- By Drug Type: Brentuximab Vedotin, Trastuzumab Emtansine (T-DM1), Inotuzumab Ozogamicin, Polatuzumab Vedotin, Enfortumab Vedotin
- By Target Antigen: HER2, CD30, CD22, CD79b, Nectin-4
- By Linker Technology: Cleavable Linkers, Non-Cleavable Linkers
- By Payload Type: Microtubule Inhibitors, DNA Damaging Agents, Topoisomerase Inhibitors
- By Indication: Breast Cancer, Lymphoma, Leukemia, Bladder Cancer, Lung Cancer
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Brentuximab Vedotin leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Cancer Antibody Drug Conjugates Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
By Drug Type 5
By Target Antigen 5
By Linker Technology 2
By Payload Type 3
By Indication 5
Companies profiled
Seagen Inc.
Roche Holding AG
Astellas Pharma Inc.
Pfizer Inc.
ImmunoGen Inc.
Amgen Inc.
Daiichi Sankyo Company
Limited
Mersana Therapeutics Inc.
Molecular Partners AG
Zymeworks Inc.
CytomX Therapeutics Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Seagen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Astellas Pharma Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ImmunoGen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Amgen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Daiichi Sankyo Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Mersana Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Molecular Partners AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Zymeworks Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CytomX Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Synaffix B.V.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sorrento Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →AbbVie Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Genmab A/S
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,405M by 2033 · 5.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Brentuximab Vedotin37.7
- Trastuzumab Emtansine (T-DM1)13.2
- Inotuzumab Ozogamicin11.7
- Polatuzumab Vedotin18.8
- Enfortumab Vedotin18.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$528.5M → $762.5M · 4.7%
Europe$368.4M → $506.6M · 4.1%
Asia Pacific$336.3M → $476.7M · 4.5%
Latin America$208.2M → $307.4M · 5.0%
Middle East and Africa$160.2M → $265.1M · 6.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.162026
5.172027
5.192028
5.192029
5.212030
5.222031
5.242032
5.242033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Seagen Inc.22.8
- Roche Holding AG21.0
- Astellas Pharma Inc.6.1
- Pfizer Inc.4.2
- ImmunoGen Inc.8.0
- Amgen Inc.9.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →By Drug Type32.9%
By Target Antigen18.0%
By Linker Technology16.9%
By Payload Type12.3%
By Indication19.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe21.9
- Asia Pacific20.6
- Latin America13.3
- Middle East and Africa11.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Seagen Inc. | 94 | 79 | 79 | 80 | 76 | 86 | 82 |
| Roche Holding AG | 93 | 89 | 77 | 69 | 73 | 91 | 82 |
| Astellas Pharma Inc. | 79 | 76 | 86 | 83 | 66 | 67 | 76 |
| Pfizer Inc. | 80 | 72 | 73 | 69 | 79 | 80 | 76 |
| ImmunoGen Inc. | 72 | 59 | 51 | 61 | 58 | 62 | 61 |
| Amgen Inc. | 56 | 65 | 65 | 59 | 60 | 70 | 63 |
| Daiichi Sankyo Company | 52 | 44 | 49 | 59 | 63 | 57 | 54 |
| Limited | 39 | 57 | 41 | 38 | 42 | 39 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Seagen Inc.
- Roche Holding AG
- Astellas Pharma Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Seagen Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Roche Holding AG | ◐ | ◐ | ✓ | − | ◐ | ✓ |
| Astellas Pharma Inc. | ◐ | ◐ | ✓ | ✓ | − | − |
| Pfizer Inc. | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| ImmunoGen Inc. | ✓ | ◐ | − | ◐ | − | ◐ |
| Amgen Inc. | − | ✓ | ◐ | ◐ | ◐ | ✓ |
| Daiichi Sankyo Company | ◐ | − | ◐ | − | − | − |
| Limited | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Seagen Inc.82
2Roche Holding AG82
3Astellas Pharma Inc.76
4Pfizer Inc.76
5Amgen Inc.63
6ImmunoGen Inc.61
7Daiichi Sankyo Company54
8Limited43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Seagen Inc.Roche Holding AG
Challenger2
Strong scale, closing on the leaders.
Astellas Pharma Inc.Pfizer Inc.
Contender2
Focused players with pockets of strength.
ImmunoGen Inc.Amgen Inc.
Niche2
Specialists in a single segment or region.
Daiichi Sankyo CompanyLimited
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land By Drug Type in North America, then scale across Cancer Antibody Drug Conjugates Market — a $485M beachhead inside a $6.41B market.
Beachhead (SOM)$485Mobtainable near-term
Serviceable (SAM)$2.61Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Brentuximab Vedotin
Best fit — highest urgency & budget in By Drug Type.
Economic buyer77 fit
Trastuzumab Emtansine (T-DM1)
Strong fit — clear ROI and a fast path to value.
End user69 fit
Inotuzumab Ozogamicin
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win By Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add By Target Antigen & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + By Linker Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel25%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For By Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cancer Antibody Drug Conjugates Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation12%
Closed-won7%
$15.5KCAC
$88KLTV
5.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cancer Antibody Drug Conjugates Market is a resilient opportunity — $3.62B by 2033, compounding at 5.6%.
TAM · 2025$2.34Btoday
TAM · 2033$3.62Bforecast
CAGR5.6%2027–2033
Cumulative$26.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.62BTotal addressable market
SAM$1.43BServiceable available market
SOM$283MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.6% CAGR
Demand compounds through 2033, outpacing GDP across By Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in By Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.62BLarge & growingTAM by 2033 at 5.6% CAGR
$1.43BServiceable nowreachable with today’s model
$283MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.82BBear3.6% CAGR
$3.62BBase5.6% CAGR
$4.63BBull7.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & By Target Antigen optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cancer Antibody Drug Conjugates Market — a $5.83B market by 2033. Plan: grow share from 10.2% to 18.9%.
Market size · 2033$5.83Btotal addressable
Market CAGR5.0%2027–2033
Target share18.9%from 10.2% today
Revenue ambition$1.10Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.2% | 18.9% | On track |
| Revenue | $576M | $1.10B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 30.7% | 43.2% | On track |
| Customer retention | 89.7% | 95.4% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in By Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build By Target Antigen capability
A defensible second engine — invest in By Target Antigen to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core By Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch By Target Antigen
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $165M capacity & capability investment
- Greenlight bolt-on M&A in By Target Antigen
- Authorise North America expansion plan
- Fund R&D program for By Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cancer Antibody Drug Conjugates Market conversation — a $1.90B market you can size, segment and defend in minutes.
Market size · 2033$1.90Btotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,309+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of By Drug Type
Goal Grow share in By Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 2 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Seagen Inc.Roche Holding AGAstellas Pharma Inc.Pfizer Inc.ImmunoGen Inc.Amgen Inc.Daiichi Sankyo CompanyLimited+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cancer Antibody Drug Conjugates Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cancer Antibody Drug Conjugates Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Virus Like Particles Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportPreimplantation Genetics Diagnosis (PGD) Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportBrucella Abortus Vaccine Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportAlcohol Excipient Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportWound Management Products Market
Market size, share, segmentation and regional forecast.
$957M market · 2025 base year
View reportFriedreich Ataxia Drug Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportTyrosine Protein Kinase JAK1 Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportLymphocyte Activation Gene 3 Protein Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportRhabdomyosarcoma Drug Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportNeuroendocrine Tumor Drug Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportTyrosine Protein Kinase SYK Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAlcohol Disinfectant Wipes Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.